RhumbLine Advisers’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-602
| Closed | -$1.05K | – | 4198 |
|
|
2026
Q1 | $1.05K | Hold |
602
| – | – | ﹤0.01% | 3974 |
|
|
2025
Q4 | $1.05K | Hold |
602
| – | – | ﹤0.01% | 4028 |
|
|
2025
Q3 | $1.41K | Hold |
602
| – | – | ﹤0.01% | 4012 |
|
|
2025
Q2 | $1.23K | Sell |
602
-41,097
| -99% | -$78.8K | ﹤0.01% | 4024 |
|
|
2025
Q1 | $68K | Buy |
41,699
+2,674
| +7% | +$5.37K | ﹤0.01% | 3496 |
|
|
2024
Q4 | $71.4K | Buy |
39,025
+999
| +3% | +$4.42K | ﹤0.01% | 3577 |
|
|
2024
Q3 | $220K | Sell |
38,026
-468
| -1% | -$3.86K | ﹤0.01% | 3187 |
|
|
2024
Q2 | $311K | Buy |
38,494
+37,857
| +5,943% | +$398K | ﹤0.01% | 2981 |
|
|
2024
Q1 | $8.84K | Sell |
637
-1
| -0.2% | -$9 | ﹤0.01% | 3891 |
|
|
2023
Q4 | $3.91K | Hold |
638
| – | – | ﹤0.01% | 4019 |
|
|
2023
Q3 | $2.98K | Sell |
638
-1,351
| -68% | -$7.46K | ﹤0.01% | 4065 |
|
|
2023
Q2 | $10.7K | Sell |
1,989
-30,498
| -94% | -$246K | ﹤0.01% | 3935 |
|
|
2023
Q1 | $320K | Buy |
32,487
+1,487
| +5% | +$25.3K | ﹤0.01% | 2594 |
|
|
2022
Q4 | $580K | Buy |
31,000
+396
| +1% | +$8.97K | ﹤0.01% | 2396 |
|
|
2022
Q3 | $634K | Buy |
30,604
+3,971
| +15% | +$102K | ﹤0.01% | 2385 |
|
|
2022
Q2 | $553K | Buy |
26,633
+2,721
| +11% | +$76.7K | ﹤0.01% | 2453 |
|
|
2022
Q1 | $1.03M | Sell |
23,912
-2,487
| -9% | -$112K | ﹤0.01% | 2119 |
|
|
2021
Q4 | $1.58M | Sell |
26,399
-165
| -0.6% | -$13.2K | ﹤0.01% | 2005 |
|
|
2021
Q3 | $2.28M | Buy |
26,564
+559
| +2% | +$56.1K | ﹤0.01% | 1834 |
|
|
2021
Q2 | $2.89M | Buy |
26,005
+7,454
| +40% | +$716K | ﹤0.01% | 1756 |
|
|
2021
Q1 | $2.07M | Buy |
18,551
+1,439
| +8% | +$189K | ﹤0.01% | 1892 |
|
|
2020
Q4 | $1.82M | Buy |
17,112
+907
| +6% | +$121K | ﹤0.01% | 1896 |
|
|
2020
Q3 | $2.26M | Sell |
16,205
-2,746
| -14% | -$573K | ﹤0.01% | 1610 |
|
|
2020
Q2 | $6.13M | Buy |
18,951
+8,016
| +73% | +$1.29M | 0.01% | 1076 |
|
|
2020
Q1 | $976K | Buy |
10,935
+215
| +2% | +$13.3K | ﹤0.01% | 1890 |
|
|
2019
Q4 | $425K | Buy |
10,720
+441
| +4% | +$13.3K | ﹤0.01% | 2434 |
|
|
2019
Q3 | $253K | Sell |
10,279
-75
| -0.7% | -$2.28K | ﹤0.01% | 2658 |
|
|
2019
Q2 | $365K | Buy |
10,354
+992
| +11% | +$39.4K | ﹤0.01% | 2502 |
|
|
2019
Q1 | $419K | Buy |
9,362
+221
| +2% | +$11.1K | ﹤0.01% | 2399 |
|
|
2018
Q4 | $439K | Buy |
9,141
+3,002
| +49% | +$182K | ﹤0.01% | 2355 |
|
|
2018
Q3 | $410K | Sell |
6,139
-438
| -7% | -$24.4K | ﹤0.01% | 2360 |
|
|
2018
Q2 | $309K | Buy |
6,577
+380
| +6% | +$21K | ﹤0.01% | 2512 |
|
|
2018
Q1 | $350K | Buy |
6,197
+221
| +4% | +$12K | ﹤0.01% | 2365 |
|
|
2017
Q4 | $296K | Sell |
5,976
-576
| -9% | -$35.7K | ﹤0.01% | 2477 |
|
|
2017
Q3 | $498K | Buy |
6,552
+111
| +2% | +$8.26K | ﹤0.01% | 2306 |
|
|
2017
Q2 | $606K | Sell |
6,441
-141
| -2% | -$12.1K | ﹤0.01% | 2203 |
|
|
2017
Q1 | $523K | Buy |
6,582
+464
| +8% | +$37K | ﹤0.01% | 2223 |
|
|
2016
Q4 | $510K | Buy |
6,118
+266
| +5% | +$24.1K | ﹤0.01% | 2212 |
|
|
2016
Q3 | $655K | Buy |
5,852
+83
| +1% | +$9.17K | ﹤0.01% | 2048 |
|
|
2016
Q2 | $640K | Sell |
5,769
-232
| -4% | -$28.2K | ﹤0.01% | 2038 |
|
|
2016
Q1 | $627K | Buy |
6,001
+104
| +2% | +$8.03K | ﹤0.01% | 2061 |
|
|
2015
Q4 | $476K | Buy |
5,897
+413
| +8% | +$32.9K | ﹤0.01% | 2266 |
|
|
2015
Q3 | $380K | Buy |
5,484
+65
| +1% | +$5.66K | ﹤0.01% | 2403 |
|
|
2015
Q2 | $531K | Buy |
5,419
+378
| +7% | +$40.4K | ﹤0.01% | 2283 |
|
|
2015
Q1 | $494K | Buy |
5,041
+875
| +21% | +$84.8K | ﹤0.01% | 2309 |
|
|
2014
Q4 | $459K | Buy |
4,166
+1,277
| +44% | +$156K | ﹤0.01% | 2323 |
|
|
2014
Q3 | $341K | Buy |
2,889
+650
| +29% | +$81K | ﹤0.01% | 2455 |
|
|
2014
Q2 | $290K | Buy |
+2,239
| New | +$264K | ﹤0.01% | 2620 |
|
Other funds holding INO
VCM
VFT
GCP
QC
RhumbLine Advisers's INO Position: Q2 2026 in Review
RhumbLine Advisers sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 602 shares — an estimated $1.05K sold.
RhumbLine Advisers first reported a position in INO in Q2 2014 and held it in 48 quarters. The position peaked at $6.13M in Q2 2020. 72 funds tracked by Wall St. Rank hold INO as of Q2 2026.
- RhumbLine Advisers reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 602 Inovio Pharmaceuticals shares in Q2 2026, an estimated $1.05K.
- RhumbLine Advisers first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 48 quarters.
- RhumbLine Advisers's Inovio Pharmaceuticals position peaked at $6.13M in Q2 2020.
- 72 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.